As contrast market founders, radiopharmaceuticals show promise

04/30/2013 | DOTMed.com

The decline in the U.S. contrast agents market is likely to last until 2017, according to this article. Companies expected to be affected include GE Healthcare, Mallinckrodt and Lantheus Medical Imaging. However, analyst Ravindra Sharma said the radiopharmaceuticals sector is a promising area. Another trend in the field is advancement not just in the chemical composition of contrast agents but in how they are administered, such as in the use of software to allow for integration of injectors, PACS and imaging devices.

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX